Cogent Biosciences News

Analysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Cogent Biosciences (COGT) and Adaptive Biotechnologies (ADPT)

TipRanksMay 8 18:10

Cogent Biosciences Price Target Maintained With a $18.00/Share by Needham

Cogent Biosciences Price Target Maintained With a $18.00/Share by Needham

Dow JonesMay 8 18:06

Needham: Reiterates the Cogent Biosciences (COGT.US) rating, adjusted from buy to buy, with a target price of $18.00.

Needham: Reiterates the Cogent Biosciences (COGT.US) rating, adjusted from buy to buy, with a target price of $18.00.

Zhitong FinanceMay 8 18:02

Needham Reiterates Buy on Cogent Biosciences, Maintains $18 Price Target

Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.

BenzingaMay 8 17:56

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)

TipRanksMay 8 17:40

Buy Recommendation for Cogent Biosciences Based on Promising Clinical Trials and Market Position

TipRanksMay 8 06:15

Cogent Biosciences (COGT.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.62 dollars, previous value was -0.54 dollars, and expected value was -0.51 dollars.

Cogent Biosciences (COGT.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.62 dollars, previous value was -0.54 dollars, and expected value was -0.51 dollars.

Zhitong FinanceMay 7 21:20

Cogent Biosciences | 10-Q: Quarterly report

Futu NewsMay 7 20:29 · Announcements

Cogent Biosciences Q1 EPS $(0.62) Misses $(0.51) Estimate

Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.51) by 21.57 percent. This is a 14.81 percent decrease over losses of

BenzingaMay 7 20:03

Press Release: Cogent Biosciences Reports First Quarter 2024 Financial Results

Cogent Biosciences Reports First Quarter 2024 Financial Results SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies

Dow JonesMay 7 20:00

Cogent Biosciences 1Q Loss/Shr 62c >COGT

Cogent Biosciences 1Q Loss/Shr 62c >COGT

Dow JonesMay 7 20:00

Cogent Biosciences: A Strong Buy on Oncology Asset Potential and Favorable Market Dynamics

TipRanksApr 30 05:05

Cogent Announces IPv4 Address Securitization Offering

WASHINGTON, April 25, 2024 /PRNewswire/ -- Cogent Communications Holdings, Inc. (NASDAQ: CCOI) (the "Company" or "Cogent") yesterday announced that a special-purpose, bankruptcy remote, indirect whol

PR NewswireApr 25 20:45

Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) fell sharply in today's pre-market trading a

BenzingaApr 15 20:19

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

Globe NewswireApr 9 21:00

COGT Reports Full Year 2023 Financial Results and Business Highlights

Yahoo FinanceFeb 28 17:32

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Celldex (CLDX) and Laboratory (LH)

TipRanksFeb 28 12:40

Cogent Biosciences Is Maintained at Overweight by JP Morgan

Cogent Biosciences Is Maintained at Overweight by JP Morgan

Dow JonesFeb 28 02:10

JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $20

JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $18 to $20.

BenzingaFeb 28 02:00

Analysts Offer Insights on Healthcare Companies: Cigna (CI), Cogent Biosciences (COGT) and Canopy Growth (CGC)

TipRanksFeb 27 20:30